RxDoctor Payments Data

Akashia Anderson, MD

Family Medicine · Murfreesboro, TNNPI 1003075862

Payments from drug & device makers

$9,590in general payments, 2019–2025

Across 519 payments — averaging $18.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$863
  • AstraZeneca$837
  • AbbVie$824
  • Lilly USA, LLC$771
  • Astellas Pharma US Inc$583
  • Novartis$498
  • plus $5K from 47 others

What the payments were for

  • Food & beverage$9,34597%
  • Education$2453%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,590 in reported general payments places this provider in the 90th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$59,381
Medicare patients
124
Services billed
1,904

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban103$80,650
OzempicSemaglutide59$61,006
RybelsusSemaglutide52$54,531
TrulicityDulaglutide43$49,900
MounjaroTirzepatide26$30,966
JardianceEmpagliflozin27$30,221
XareltoRivaroxaban39$23,863
VraylarCariprazine Hcl15$23,775
Nucynta ErTapentadol Hcl32$20,176
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$16,322
JanuviaSitagliptin Phosphate17$15,061
FarxigaDapagliflozin Propanediol17$14,408
KerendiaFinerenone15$9,316
GemtesaVibegron16$9,190
Tresiba Flextouch U-100Insulin Degludec22$8,606

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$863$115,537111 claims
Lilly USA, LLCTrulicity, Mounjaro, Olanzapine$771$82,50287 claims
PfizerEliquis$479$80,650103 claims
AstraZenecaBreztri Aerosphere, Farxiga$837$30,73042 claims
Boehringer IngelheimJardiance$386$30,22127 claims
Johnson & JohnsonXarelto$215$23,86339 claims
AbbVieVraylar$824$23,77515 claims
MerckJanuvia$359$15,06117 claims
BayerKerendia$421$9,31615 claims
Sumitomo Pharma America, Inc.Gemtesa$193$9,19016 claims
GSKTrelegy Ellipta$182$7,11111 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$369$6,58312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Murfreesboro

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →